1. Home
  2. CBRE vs TOVX Comparison

CBRE vs TOVX Comparison

Compare CBRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBRE
  • TOVX
  • Stock Information
  • Founded
  • CBRE 1906
  • TOVX 2001
  • Country
  • CBRE United States
  • TOVX United States
  • Employees
  • CBRE N/A
  • TOVX N/A
  • Industry
  • CBRE Real Estate
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBRE Finance
  • TOVX Health Care
  • Exchange
  • CBRE Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • CBRE 41.3B
  • TOVX 3.8M
  • IPO Year
  • CBRE 2004
  • TOVX 2006
  • Fundamental
  • Price
  • CBRE $143.18
  • TOVX $0.44
  • Analyst Decision
  • CBRE Buy
  • TOVX Hold
  • Analyst Count
  • CBRE 9
  • TOVX 1
  • Target Price
  • CBRE $152.11
  • TOVX N/A
  • AVG Volume (30 Days)
  • CBRE 1.4M
  • TOVX 238.4K
  • Earning Date
  • CBRE 07-29-2025
  • TOVX 08-12-2025
  • Dividend Yield
  • CBRE N/A
  • TOVX N/A
  • EPS Growth
  • CBRE 2.39
  • TOVX N/A
  • EPS
  • CBRE 3.28
  • TOVX N/A
  • Revenue
  • CBRE $36,742,000,000.00
  • TOVX N/A
  • Revenue This Year
  • CBRE $14.60
  • TOVX N/A
  • Revenue Next Year
  • CBRE $9.27
  • TOVX N/A
  • P/E Ratio
  • CBRE $43.72
  • TOVX N/A
  • Revenue Growth
  • CBRE 13.15
  • TOVX N/A
  • 52 Week Low
  • CBRE $86.19
  • TOVX $0.40
  • 52 Week High
  • CBRE $147.75
  • TOVX $7.37
  • Technical
  • Relative Strength Index (RSI)
  • CBRE 69.90
  • TOVX 36.05
  • Support Level
  • CBRE $134.35
  • TOVX $0.42
  • Resistance Level
  • CBRE $140.59
  • TOVX $0.46
  • Average True Range (ATR)
  • CBRE 2.89
  • TOVX 0.03
  • MACD
  • CBRE 0.61
  • TOVX 0.02
  • Stochastic Oscillator
  • CBRE 88.77
  • TOVX 25.00

About CBRE CBRE Group Inc

CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: